Cost effectiveness of heptavalent pneumococcal conjugate vaccine in populations of high risk in Colombia

Colombia Medica

Volumn 41, Issue 4, 2010, Pages 315-322

  Guzmán, Nelson Alvis ^a   De La Hoz, Fernando ^b  

^a UNIVERSIDAD DE CARTAGENA   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Cost effectiveness; High risk; Pneumococcal vaccine; Pneumonia; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; CHILDHOOD MORTALITY; COHORT ANALYSIS; COLOMBIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; MEDICAL DECISION MAKING; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR;

EID: 78650720491     PISSN: 01208322     EISSN: 16579534     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Agudelo CI, Moreno J, Sanabria OM, Ovalle MV, Di Fabio JL, Castañeda E. Streptococcus pneumoniae: serotype evolution and patterns of antimicrobial susceptibility in invasive isolates from 11 years surveillance (1994-2004) in Colombia. Biomedica. 2006;26:234-49.
2. Di Fabio JL, Castaneda E, Agudelo CI, De La HF, Hortal M, Camou T, et al. Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin America, Sireva-Vigia Group, 1993 to 1999. PAHO Sireva-Vigia Study Group. Pan American Health Organization. Pediatr Infect Dis J. 2001;20:959-67.
3. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Costeffectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ. 2008;9:7-15.
4. Finn A, Booy R, Moxon R, Sharland M, Heath P. Should the new pneumococcal vaccine be used in high-risk children? Arch Dis Child. 2002;87:18-21.
5. Mahon BE, Ehrenstein V, Norgaard M, Pedersen L, Rothman KJ, Sorensen HT. Perinatal risk factors for hospitalization for pneumococcal disease in childhood: a population-based cohort study. Pediatrics. 2007;119: e804-12.
6. Constenla D, Gómez E, De la Hoz F, O'Loughlin R, Sinha A, Valencia J, et al. The burden of pneumococcal disease and the cost effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: A review of the evidence and a preliminary economic analysis. Washington, DC: The Albert B. Sabin Vaccine Institute (SVI); 2007. [fecha de acceso en noviembre de 2007]. URL disponible en: http://www.sabin.org/files/attachment sabinreportfinal2.pdf
7. Tregnaghi M, Ceballos A, Ruttimann R, Ussher J, Tregnaghi P, Peeters P, et al. Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina. Pediatr Infect Dis J. 2006;25:370-2.
8. Lagos R, Muñoz A, Valenzuela MT, Heitmann I, Levine MM. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. Pediatr Infect Dis J. 2002;21:1115-23.
9. Lagos Zuccone R, San Martín B O, Erazo L A, Avendaño- Bertoló A, Levine M. Epidemiología de las enfermedades invasoras causadas por Streptococcus pneumoniae en niños chilenos: proyecciones clínicas y de salud pública. Rev Chil Infectol. 2001;18:15-21.
10. Dickinson FO, Pérez AE. Bacterial meningitis in children and adolescents: an observational study based on the national surveillance system. BMC Infect Dis. 2005;5:103.
11. Reis JN, Cordeiro SM, Coppola SJ, Salgado K, Carvalho MG, Teixeira LM, et al. Population-based survey of antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, Brazil. J Clin Microbiol. 2002;40:275-7.
12. Asturias EJ, Soto M, Menéndez R, Ramírez PL, Recinos F, Gordillo R, et al. Meningitis and pneumonia in Guatemalan children: the importance of Haemophilus influenzae type b and Streptococcus pneumoniae. Rev Panam Salud Publica. 2003;14:377-84.
13. Hortal M E M, Iraola I, De Mucio B. A population-based assessment of the disease burden of consolidated pneumonia in hospitalized children under five years of age. Int J Infect Dis. 2007;11:273-7.
14. Barreto M L S L, Assis AM, Araujo MP, Farenzena GG, Santos PA, et al. Effect of vitamin A supplementation on diarrhoea and acute lower-respiratory- tract infections in young children in Brazil. Lancet. 1994;344:228-31.
15. Gentile A, Ruvinsky R, Bakir J, Gentile F, Kupervaser M, Quiriconi M, et al. Surveillance of probably bacterial pneumonia (PBP) in children less than 5 years old in two geographical areas in Argentina. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Microbiology Society; 2005.
16. Lagos R M A, Espinoza A, Moene K, Hausdorff W, Ruttimann R, et al. Population-based surveillance for suspected (S) and radiologically-confirmed (RxC) community acquired pneumonia (CAP) in children 1-35 months of age (MoA), in 6 municipalities (Mn) of the metropolitan region (MR), Chile. 5th International Symposium on Pneumococci and Pneumococcal Diseases 2006. Alice Springs, Elsevier.
17. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-95.
18. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-5.
19. WHO. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
20. De La Hoz F, Higuera AB, Di Fabio JL, Luna M, Naranjo AG, de la Luz Valencia M, et al. Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine. 2004;23:36-42.
21. Wisloff T, Abrahamsen TG, Bergsaker MA, Lovoll O, Moller P, Pedersen MK, et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine. 2006;24:5690-9.
22. De Wals P, Petit G, Erickson LJ, Guay M, Tam T, Law B, et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine. 2003;21:3757-64.
23. Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: a review (2002-2006). Vaccine. 2007;25:1355-67.
24. Simoes E, Cherian T, Chow J, Shahid-Salles S, Laxminarayan R, T. J. Acute respiratory infections in children. In: Jamison D, Breman J, Measham A, Alleyne G, Claeson M, Evans D, et al. (eds). Disease control priorities in developing countries. 2nd ed. New York: The World Bank; 2006. p. 483-97.